Participate in Research for Hypertrophic Cardiomyopathy (HCM)
Learn about clinical trials looking at a potential therapy to address mutations in the MYBPC3 gene, the leading genetic cause of HCM.
A Phase 1b clinical trial of an investigational gene therapy called TN-201 for the treatment of HCM caused by mutations in the MYBPC3 gene.
A natural history study designed to collect and evaluate information on how cardiomyopathy changes over time in infants, children, and teens with the MYBPC3 gene mutation. This study only involves review of your medical records and blood draw.
About Hypertrophic Cardiomyopathy (HCM)
HCM is a condition that increases the thickness of the heart muscle, which can limit the heart’s ability to function effectively.
Gene Therapy for
HCM
By delivering a working gene to heart muscle cells, gene therapy has the potential to correct the underlying cause of genetic heart conditions, like HCM.
Contact Us
For more information about taking part in research for MYBPC3-associated HCM, complete this form or contact our Patient Advocacy team by email at patient.advocacy@tenayathera.com or phone at (650) 825-6990 option 4.
